Aktis Oncology, Inc.

AI-generated fair value estimate for this company.

Method: Net cash plus risk-adjusted platform value: $517.32M cash less $11.24M debt = $506.08M net cash (about $9.10 per share on 55.62 million shares); added an estimated $9.50 per share of platform value for its radiopharmaceutical/targeted-alpha-therapy pipeline, informed by comparable large radiopharma platform transactions (e.g. Bristol Myers Squibb's roughly $4.1B acquisition of RayzeBio) scaled down heavily to reflect Aktis's earlier, largely preclinical/early-clinical stage.

Reasoning: As a company that only IPO'd in early 2026 and remains pre-revenue and clinical-stage, Aktis has no meaningful operating cash flow to discount; net cash sets a hard floor, and a conservative, comparable-transaction-based platform value captures option value from its pipeline without assuming clinical success.